自身免疫性神经病中的抗体:检测什么、如何检测、为何检测
本文综述自身免疫性神经病中抗体的临床应用。吉兰-巴雷综合征(GBS)诊断基于临床标准,不要求常规检测抗神经节苷脂抗体,但抗GM1 IgG、抗GQ1b IgG和抗GD1b IgG可分别支持GBS、Miller Fisher综合征和急性感觉共济失调综合征的诊断。抗髓鞘相关糖蛋白(MAG)IgM和抗双唾液酸基IgM抗体有助于诊断抗MAG神经病和CANOMAD谱神经病并与CIDP鉴别。抗接触蛋白-1、接触蛋白相关蛋白1及neurofascin(NF140、NF186或NF155)抗体定义了具有特定临床和病理特征的自身免疫性结旁病亚组,已纳入临床常规检测。
要点
- GBS诊断基于临床标准,不要求常规检测抗神经节苷脂抗体。
- 抗GM1 IgG、抗GQ1b IgG和抗GD1b IgG可分别支持诊断不确定的GBS、Miller Fisher综合征和急性感觉共济失调综合征。
- 抗MAG IgM和抗双唾液酸基IgM抗体有助于诊断抗MAG神经病和CANOMAD谱神经病并与CIDP鉴别。
核心结论
- 自身免疫性神经病中致病抗体的检测具有诊断和治疗意义,已促使GBS和CIDP诊断算法修改。
研究设计与样本
- 综述,旨在为普通神经科医生提供自身免疫性神经病临床评估中抗体使用的实用视角。
主要发现
- GBS诊断基于临床标准,不要求系统检测抗神经节苷脂抗体。
- 当GBS(GM1 IgG)、Miller Fisher(GQ1b IgG)或急性感觉共济失调(GD1b IgG)综合征诊断不确定时,抗神经节苷脂抗体阳性可支持临床怀疑。
- 抗MAG IgM和抗双唾液酸基IgM抗体分别是诊断抗MAG神经病和CANOMAD谱神经病的关键,并有助于与CIDP鉴别。
- 抗接触蛋白-1、接触蛋白相关蛋白1及neurofascin(NF140、NF186或NF155)抗体定义的患者亚组具有对传统治疗反应差或部分反应、对抗CD20治疗反应极佳以及无炎症情况下结区破坏的临床和病理特征。
关键数值与推荐
- GBS诊断基于临床标准,不要求系统检测抗神经节苷脂抗体。
- 抗GM1 IgG、抗GQ1b IgG和抗GD1b IgG可分别支持诊断不确定的GBS、Miller Fisher综合征和急性感觉共济失调综合征。
- 抗MAG IgM和抗双唾液酸基IgM抗体分别是诊断抗MAG神经病和CANOMAD谱神经病的关键。
- 抗接触蛋白-1、接触蛋白相关蛋白1及neurofascin(NF140、NF186或NF155)抗体定义了自身免疫性结旁病诊断类别。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune neuropathies are a heterogeneous group of immune-mediated disorders of the peripheral nerves. Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are the archetypal acute and chronic forms. Over the past few decades, pathogenic antibodies targeting antigens of the peripheral nervous system and driving peripheral nerve damage in selected patients have been described. Moreover, the detection of these antibodies has diagnostic and therapeutic implications that have prompted a modification of the GBS and CIDP diagnostic algorithms. GBS diagnosis is based in clinical criteria, and systematic testing of anti-ganglioside antibodies is not required. Nonetheless, a positive anti-ganglioside antibody test may support the clinical suspicion when diagnosis of GBS (GM1 IgG), Miller Fisher (GQ1b IgG), or acute sensory-ataxic (GD1b IgG) syndromes is uncertain. Anti-myelin-associated glycoprotein (MAG) IgM and anti-disialosyl IgM antibodies are key in the diagnosis of anti-MAG neuropathy and chronic ataxic neuropathy, ophthalmoplegia, M-protein, cold agglutinins, and disialosyl antibodies spectrum neuropathies, respectively, and help differentiating these conditions from CIDP. Recently, the field has been boosted by the discovery of pathogenic antibodies targeting proteins of the node of Ranvier contactin-1, contactin-associated protein 1, and nodal and paranodal isoforms of neurofascin (NF140, NF186, or NF155). These antibodies define subgroups of patients with specific clinical (most importantly poor or partial response to conventional therapies and excellent response to anti-CD20 therapy) and pathologic (node of Ranvier disruption in the absence of inflammation) features that led to the definition of the "autoimmune nodopathy" diagnostic category and to the incorporation of nodal/paranodal antibodies to clinical routine testing. The purpose of this review was to provide a practical vision for the general neurologist of the use of antibodies in the clinical assessment of autoimmune neuropathies.
引用
- Pascual-Goñi E, Caballero-Ávila M, Querol L, et al. Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test. Neurology. 2024. PMID: 39088795. doi:10.1212/WNL.0000000000209725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。